Holland & Knight advised Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, in connection with a $100 million underwritten common stock offering. The offering was priced on June 27 and announced on June 28.
The offering included the following investors: Bain Capital Life Sciences, Farallon Capital Management, Frazier Life Sciences, Wellington Management, Nantahala Capital, TCGX and First Light Asset Management, among others.
Jefferies, Piper Sandler and Guggenheim Securities acted as joint book-running managers for the offering. Oppenheimer & Co. was the lead manager.
Savara, which is based in Langhorne, Pennsylvania, intends to use proceeds from the offering for working capital and general corporate purposes, which include, but are not limited to, the funding of clinical development of and pursuing regulatory approval for molgramostim, investing in its commercialization infrastructure and supply, commercial launch preparation activities in the United States, European Union and Japan, and general and administrative expenses.
Holland & Knigh's team representing Savara included Partners Shawn Turner, Mark Goldschmidt and Kimberly Thibault and Associates Jonathan Guest, Stephanie Torres and Claire Lydiard.
Original source can be found here.